| Index | - | P/E | 43.49 | EPS (ttm) | 4.26 | Insider Own | 0.15% | Shs Outstand | 77.15M | Perf Week | 8.87% |
| Market Cap | 14.29B | Forward P/E | 15.68 | EPS next Y | 11.82 | Insider Trans | -20.68% | Shs Float | 76.35M | Perf Month | 6.54% |
| Enterprise Value | 16.86B | PEG | 3.75 | EPS next Q | - | Inst Own | - | Short Float | 3.67% | Perf Quarter | 9.77% |
| Income | 329.00M | P/S | 1.73 | EPS this Y | -17.98% | Inst Trans | - | Short Ratio | 3.45 | Perf Half Y | 81.34% |
| Sales | 8.25B | P/B | 1.52 | EPS next Y | 11.87% | ROA | 2.01% | Short Interest | 2.80M | Perf YTD | 1.67% |
| Book/sh | 121.55 | P/C | 15.40 | EPS next 5Y | 11.61% | ROE | 3.54% | 52W High | 203.91 -9.14% | Perf Year | -3.81% |
| Cash/sh | 12.03 | P/FCF | 10.62 | EPS past 3/5Y | -22.08% -14.21% | ROIC | 4.80% | 52W Low | 66.57 178.31% | Perf 3Y | -18.25% |
| Dividend Est. | - | EV/EBITDA | 13.54 | Sales past 3/5Y | 2.15% 24.15% | Gross Margin | 21.85% | Volatility | 5.33% 4.63% | Perf 5Y | -32.64% |
| Dividend TTM | - | EV/Sales | 2.04 | EPS Y/Y TTM | -55.30% | Oper. Margin | 10.15% | ATR (14) | 8.03 | Perf 10Y | 140.49% |
| Dividend Ex-Date | - | Quick Ratio | 0.95 | Sales Y/Y TTM | -0.35% | Profit Margin | 3.99% | RSI (14) | 65.35 | Recom | 2.50 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.95 | EPS Q/Q | -19.75% | SMA20 | 8.86% | Beta | 1.20 | Target Price | 173.82 |
| Payout | 0.00% | Debt/Eq | 0.38 | Sales Q/Q | 2.28% | SMA50 | 9.80% | Rel Volume | 1.18 | Prev Close | 185.43 |
| Employees | 40,200 | LT Debt/Eq | 0.33 | Earnings | Oct 27 | SMA200 | 27.46% | Avg Volume | 864.40K | Price | 185.27 |
| IPO Date | May 15, 1998 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.57% 2.95% | Net Debt/EBITDA | 2.06 | Volume | 1,017,948 | Change | -0.09% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-30-26 | Resumed | UBS | Neutral | $160 → $195 |
| Jul-31-26 | Reiterated | Robert W. Baird | $192 → $194 | |
| Jun-30-26 | Upgrade | Truist Securities | Hold → Buy | $159 → $207 |
| Jun-26-26 | Reiterated | Mizuho | Outperform | $216 → $190 |
| Jun-25-26 | Reiterated | Robert W. Baird | $168 → $186 | |
| Jun-25-26 | Upgrade | RBC Capital | Sector Perform → Outperform | $126 → $185 |
| Jun-25-26 | Reiterated | Barclays | Equal Weight | $200 → $175 |
| Jun-25-26 | Reiterated | BMO Capital | Outperform | $100 → $187 |
| Jun-24-26 | Reiterated | UBS | Buy | $150 → $160 |
| Jun-24-26 | Reiterated | Barclays | Equal Weight | $200 → $175 |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 8,253 | 8,251 | 8,282 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 6,450 | 6,076 | 5,845 | — | — | — | — | — | — | |
| Gross Profit | 1,804 | 2,176 | 2,436 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 772 | 780 | 728 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 193 | 383 | 611 | — | — | — | — | — | — | |
| Operating Income | 838 | 1,012 | 1,098 | — | — | — | — | — | — | |
| Interest Expense | 187 | 188 | 237 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -233 | -572 | 9 | — | — | — | — | — | — | |
| Net Income Before Taxes | 418 | 252 | 869 | — | — | — | — | — | — | |
| Income Taxes | 90 | 23 | 78 | — | — | — | — | — | — | |
| Consolidated Net Income | 329 | 229 | 791 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 329 | 229 | 791 | — | — | — | — | — | — | |
| Net Income | 329 | 229 | 791 | — | — | — | — | — | — | |
| EPS (Recurring) | 4.29 | 2.92 | 9.60 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 4.29 | 2.92 | 9.60 | — | — | — | — | — | — | |
| EPS (Diluted) | 4.26 | 2.90 | 9.53 | — | — | — | — | — | — | |
| EBITDA | 1,245 | 824 | 1,564 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 43.49 | 62.83 | 22.01 | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.73 | 1.72 | 2.08 | — | — | — | — | — | — | |
| Gross Margin | 21.86 | 26.37 | 29.41 | — | — | — | — | — | — | |
| Operating Margin | 10.15 | 12.27 | 13.26 | — | — | — | — | — | — | |
| Net Margin | 3.99 | 2.78 | 9.55 | — | — | — | — | — | — | |
| Shares Outstanding | 77 | 78 | 82 | — | — | — | — | — | — | |
| Market Capitalization | 14,266 | 14,213 | 17,196 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Murphy Ronan Martin | Director | Sep 17 '26 | Option Exercise | 125.74 | 5,005 | 629,329 | 8,852 | Sep 18 |
| Murphy Ronan Martin | Director | Sep 17 '26 | Sale | 175.00 | 5,005 | 875,875 | 3,847 | Sep 18 |
| McCague Eugene Pacelli | Director | Sep 17 '26 | Option Exercise | 125.74 | 3,255 | 409,284 | 7,066 | Sep 18 |
| McCague Eugene Pacelli | Director | Sep 17 '26 | Sale | 175.00 | 3,255 | 569,625 | 3,811 | Sep 18 |
| CLIMAX JOHN DR | Director | Sep 16 '26 | Sale | 175.00 | 5,005 | 875,875 | 2,087 | Sep 18 |
| CLIMAX JOHN DR | Director | Sep 16 '26 | Option Exercise | 125.74 | 5,005 | 629,329 | 7,092 | Sep 18 |
| CLIMAX JOHN DR | Director | Aug 11 '26 | Sale | 164.29 | 841 | 138,168 | 2,087 | Aug 12 |
| O'Neill Julie | Director | Aug 11 '26 | Sale | 164.29 | 915 | 150,326 | 3,515 | Aug 12 |
| Clerkin Nigel Bernard John | Chief Financial Officer | Aug 11 '26 | Sale | 164.29 | 2,267 | 372,445 | 5,881 | Aug 12 |
| Grais Linda | Director | Aug 11 '26 | Sale | 164.29 | 841 | 138,169 | 6,162 | Aug 12 |
| Murray Ciaran | Director | Aug 11 '26 | Sale | 164.29 | 2,677 | 439,804 | 20,452 | Aug 12 |
| Whitaker Anne Clem | Director | Aug 11 '26 | Sale | 164.29 | 841 | 138,167 | 891 | Aug 12 |
| Murphy Ronan Martin | Director | Aug 11 '26 | Sale | 164.29 | 841 | 138,167 | 3,847 | Aug 12 |
| McCague Eugene Pacelli | Director | Aug 11 '26 | Sale | 164.29 | 841 | 138,167 | 3,811 | Aug 12 |
| CLIMAX JOHN DR | Director | Aug 10 '26 | Option Exercise | 0.00 | 1,732 | 0 | 2,928 | Aug 12 |